Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8394382 | Toxicon | 2018 | 19 Pages |
Abstract
Although BoNT is safe and effective in the treatment of the majority of patients with CD, approximately one third discontinue. The increasing awareness of a significant proportion of patients who discontinue should encourage further efforts to optimize administration of BoNT, to improve BoNT preparations to extend duration or reduce side effects, to develop add-on therapies that may mitigate swings in symptom severity, or develop entirely novel treatment approaches.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
H.A. Jinnah, Cynthia L. Comella, Joel Perlmutter, Codrin Lungu, Mark Hallett, for the Dystonia Coalition Investigators for the Dystonia Coalition Investigators,